Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. It focuses on developing its lead drug candidate MetaBlok, which is in Phase II for the treatment or prevention of dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver, or kidneys. The company also develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial infections, primarily in the lungs and wounds, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. In addition, the company develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.